CO5550431A2 - Cristales que incluyen una sal de acido malico de n-[2 (dietilamino)etil]-5-[(5-fluoro-2oxo-3h-indol-3-ilideno) metil]-2,4-dimetil-1h-pirrol-3-carboxamida, proceso para su preparacion y composiciones de esta - Google Patents

Cristales que incluyen una sal de acido malico de n-[2 (dietilamino)etil]-5-[(5-fluoro-2oxo-3h-indol-3-ilideno) metil]-2,4-dimetil-1h-pirrol-3-carboxamida, proceso para su preparacion y composiciones de esta

Info

Publication number
CO5550431A2
CO5550431A2 CO04002781A CO04002781A CO5550431A2 CO 5550431 A2 CO5550431 A2 CO 5550431A2 CO 04002781 A CO04002781 A CO 04002781A CO 04002781 A CO04002781 A CO 04002781A CO 5550431 A2 CO5550431 A2 CO 5550431A2
Authority
CO
Colombia
Prior art keywords
malic acid
carboxamide
fluoro
methyl
ilideno
Prior art date
Application number
CO04002781A
Other languages
English (en)
Inventor
Michael Hawley
Thomas J Fleck
Stephen P Prescott
Mark T Maloney
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23211067&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5550431(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of CO5550431A2 publication Critical patent/CO5550431A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

1.- Un cristal anhidro que comprende una sal de ácido málico de un compuesto que tiene la estructura : 2.- El cristal de la reivindicación 1, en donde el ácido málico es ácido L -málico.3.- El cristal anhidro que comprende una sal de ácido málico de N-[2-(dietilamino)etil]-5-[(5-fluoro-1,2-dihidro-2-oxo-3H-indol-3-ilideno)metil]-2,4-dimetil-1H-pirrol-3-carboxamida.
CO04002781A 2001-08-15 2004-01-16 Cristales que incluyen una sal de acido malico de n-[2 (dietilamino)etil]-5-[(5-fluoro-2oxo-3h-indol-3-ilideno) metil]-2,4-dimetil-1h-pirrol-3-carboxamida, proceso para su preparacion y composiciones de esta CO5550431A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31235301P 2001-08-15 2001-08-15

Publications (1)

Publication Number Publication Date
CO5550431A2 true CO5550431A2 (es) 2005-08-31

Family

ID=23211067

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04002781A CO5550431A2 (es) 2001-08-15 2004-01-16 Cristales que incluyen una sal de acido malico de n-[2 (dietilamino)etil]-5-[(5-fluoro-2oxo-3h-indol-3-ilideno) metil]-2,4-dimetil-1h-pirrol-3-carboxamida, proceso para su preparacion y composiciones de esta

Country Status (43)

Country Link
US (2) US20030069298A1 (es)
EP (3) EP3168218B1 (es)
JP (1) JP4159988B2 (es)
KR (1) KR100639281B1 (es)
CN (2) CN100439360C (es)
AP (1) AP1660A (es)
AR (1) AR036261A1 (es)
AU (1) AU2002324684B2 (es)
BG (1) BG108553A (es)
BR (1) BR0211612A (es)
CA (1) CA2455050C (es)
CO (1) CO5550431A2 (es)
CU (1) CU23713B7 (es)
CY (1) CY1121552T1 (es)
CZ (1) CZ2004196A3 (es)
DK (2) DK3168218T3 (es)
EA (1) EA006445B9 (es)
EC (1) ECSP044975A (es)
ES (3) ES2705063T3 (es)
GE (1) GEP20063777B (es)
HK (2) HK1066542A1 (es)
HR (1) HRP20040112B1 (es)
HU (1) HU229206B1 (es)
IL (1) IL160097A0 (es)
IS (1) IS7147A (es)
MA (1) MA27058A1 (es)
ME (1) ME00414B (es)
MX (1) MXPA04001452A (es)
MY (1) MY139383A (es)
NO (1) NO326508B1 (es)
NZ (1) NZ531232A (es)
OA (1) OA12650A (es)
PL (1) PL216524B1 (es)
PT (2) PT3168218T (es)
RS (1) RS53251B (es)
SI (2) SI3168218T1 (es)
SK (1) SK902004A3 (es)
TN (1) TNSN04028A1 (es)
TR (1) TR201900509T4 (es)
TW (1) TWI269796B (es)
UA (1) UA76483C2 (es)
WO (1) WO2003016305A1 (es)
ZA (1) ZA200400706B (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100439360C (zh) 2001-08-15 2008-12-03 法玛西雅厄普约翰美国公司 包括n-[2-(二乙氨基)乙基]-5-[(5-氟-2-氧代-3h-吲哚-3-亚基)甲基]-2,4-二甲基-1h-吡咯-3-甲酰胺的苹果酸盐的晶体、其制备方法和其组合物
TW200418836A (en) * 2002-09-10 2004-10-01 Pharmacia Italia Spa Formulations comprising an indolinone compound
KR20060058728A (ko) * 2003-10-02 2006-05-30 파마시아 앤드 업존 캄파니 엘엘씨 피롤-치환된 인돌리논 화합물의 염 및 다형체
US20060009510A1 (en) * 2004-07-09 2006-01-12 Pharmacia & Upjohn Company Llc Method of synthesizing indolinone compounds
PT1773811E (pt) * 2004-07-22 2010-10-19 Lilly Co Eli Um hidrato cristalino variável de sal de hemissuccinato de (s)-6-(4-(2-((3-(9h-carbazol-4-iloxi)-2- hidroxipropil)amino)-2-metilpropil)fenoxi)-3-piridinicarbox amida
MX2007014087A (es) * 2005-05-12 2008-02-07 Pfizer Combinaciones y procedimientos para usar un compuesto de indolinona.
US20080275101A1 (en) * 2005-09-19 2008-11-06 Pfizer Inc. Solid Salt Forms Of A Pyrrole Substituted 2-Indolinone
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
US20100256392A1 (en) * 2007-11-21 2010-10-07 Teva Pharmaceutical Industries Ltd. Polymorphs of sunitinib base and processes for preparation thereof
CA2699305A1 (en) 2007-11-21 2009-05-28 Teva Pharmaceutical Industries Ltd. Polymorphs of sunitinib base and processes for preparation thereof
EP2229380A1 (en) * 2007-12-12 2010-09-22 Medichem, S.A. Polymorphic forms of a 3-pyrrole substituted 2-indolinone
EP2090306A1 (en) 2008-02-13 2009-08-19 Ratiopharm GmbH Pharmaceutical compositions comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
EP2113248A1 (en) 2008-04-29 2009-11-04 Ratiopharm GmbH Pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-,4-dimethyl-1H-pyrrole-3-carboxamide
WO2009104021A2 (en) * 2008-02-21 2009-08-27 Generics [Uk] Limited Novel polymorphs and processes for their preparation
EP2098521A1 (en) * 2008-03-06 2009-09-09 Ratiopharm GmbH Crystal forms of N-[2-(diethylamino) ethyl]-5-[fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrolle-3-carboxamide and methods for their prepparation
WO2009124037A1 (en) * 2008-03-31 2009-10-08 Teva Pharmaceutical Industries Ltd. Processes for preparing sunitinib and salts thereof
WO2009128083A1 (en) * 2008-04-16 2009-10-22 Natco Pharma Limited Novel polymorphic forms of sunitinib base
CN102066362B (zh) * 2008-05-23 2014-07-30 上海医药工业研究院 二氢吲哚酮衍生物
AR072117A1 (es) * 2008-06-13 2010-08-04 Medichem Sa Procedimiento para preparar una sal de malato 3-pirrol sustituido 2-indolinona, intermediario de sintesis y una composicion farmaceutica que la comprende.
EP2138167A1 (en) 2008-06-24 2009-12-30 ratiopharm GmbH Pharmaceutical composition comprising N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
WO2009156837A2 (en) * 2008-06-26 2009-12-30 Medichem, S.A. Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt
CA2730079A1 (en) * 2008-07-10 2010-01-14 Generics [Uk] Limited Processes for the preparation of crystalline forms of sunitinib malate
WO2010010454A2 (en) 2008-07-24 2010-01-28 Medichem, S.A. Crystalline forms of a 3-pyrrole substituted 2-indolinone malate salt
US8618309B2 (en) * 2008-07-24 2013-12-31 Teva Pharmaceutical Industries Ltd. Sunitinib and salts thereof and their polymorphs
AU2009286521A1 (en) * 2008-08-25 2010-03-04 Generics [Uk] Limited Novel polymorphs of sunitinib and processes for their preparation
EP2315764A2 (en) * 2008-08-25 2011-05-04 Generics [UK] Limited Crystalline form of sunitinib and processes for its preparation
CN102177155A (zh) * 2008-10-10 2011-09-07 麦迪凯姆股份公司 一种3-吡咯取代的2-吲哚酮苹果酸盐的制备工艺
EP2181991A1 (en) 2008-10-28 2010-05-05 LEK Pharmaceuticals D.D. Novel salts of sunitinib
EP2186809A1 (en) * 2008-11-13 2010-05-19 LEK Pharmaceuticals D.D. New crystal form of sunitinib malate
EP2896618A1 (en) 2009-01-02 2015-07-22 Hetero Research Foundation Polymorphs of sunitinib malate
TW201920110A (zh) 2009-01-16 2019-06-01 美商艾克塞里克斯公司 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
EP2255792A1 (en) 2009-05-20 2010-12-01 Ratiopharm GmbH Pharmaceutical compositions for N-[2-(Diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-dimenthyl-1H-pyrrole-3-carboxamide
WO2011004200A1 (en) 2009-07-10 2011-01-13 Generics [Uk] Limited Novel pyrrole derivatives
AU2010296849A1 (en) 2009-09-16 2012-05-03 Ranbaxy Laboratories Limited Salts of sunitinib
EP2499133A2 (en) 2009-11-12 2012-09-19 Ranbaxy Laboratories Limited Process for the preparation of crystalline form i of l-malic acid salt of sunitinib
US8916716B2 (en) 2009-11-19 2014-12-23 Ranbaxy Laboratories Limited Process for the preparation of crystalline form II of L-malic acid salt of sunitinib
WO2011092664A1 (en) 2010-01-29 2011-08-04 Ranbaxy Laboratories Limited Crystalline forms of l-malic acid salt of sunitinib
WO2011100325A2 (en) 2010-02-09 2011-08-18 Sicor Inc. Polymorphs of sunitinib salts
WO2011104555A2 (en) 2010-02-25 2011-09-01 Generics [Uk] Limited Novel process
EP2542550A1 (en) 2010-03-04 2013-01-09 Ranbaxy Laboratories Limited Process for the direct preparation of malic acid salt of sunitinib
CA2793359A1 (en) 2010-03-18 2011-09-22 Ranbaxy Laboratories Limited Process for the preparation of malic acid salt of sunitinib
WO2011128699A2 (en) 2010-04-16 2011-10-20 Generics [Uk] Limited Novel process
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
EP3536708A1 (en) 2011-04-19 2019-09-11 Pfizer Inc Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
ES2709110T3 (es) 2012-03-23 2019-04-15 Laurus Labs Ltd Un proceso mejorado para la preparación de sunitinib y sus sales de adición de ácido
PL399027A1 (pl) 2012-04-27 2013-10-28 Instytut Farmaceutyczny Sposób otrzymywania N-[2-(dietylamino)etylo]-5-formylo-2,4-dimetylo-1H-pirolo-3-karboksyamidu o wysokiej czystosci i jego zastosowanie do wytwarzania sunitynibu
RU2737765C2 (ru) 2012-05-04 2020-12-02 Пфайзер Инк. Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин
US9604968B2 (en) * 2013-10-18 2017-03-28 Sun Pharmaceutical Industries Limited Pure crystalline Form II of L-malic acid salt of sunitinib and processes for its preparation
CA2838585A1 (en) 2013-10-18 2015-04-18 Hari Babu Matta An ascorbic acid salt of sunitinib
BR112016008806A2 (pt) 2013-11-01 2017-10-03 Pfizer Vetores para expressão de antígenos associados à próstata
CN104693187A (zh) * 2013-12-10 2015-06-10 安杰世纪生物科技（北京）有限公司 一种舒尼替尼L-苹果酸盐晶型λ及其制备方法
CN104744442B (zh) * 2013-12-25 2019-05-28 江苏豪森药业集团有限公司 苹果酸舒尼替尼的制备方法
RU2567535C1 (ru) * 2014-10-01 2015-11-10 Олег Ростиславович Михайлов КРИСТАЛЛИЧЕСКАЯ ε-МОДИФИКАЦИЯ N-[2-(ДИЭТИЛАМИНО)ЭТИЛ]-5-[(Z)-(5-ФТОР-1,2-ДИГИДРО-2-ОКСО-3Н-ИНДОЛ-3-ИЛИДЕН)МЕТИЛ]-2,4-ДИМЕТИЛ-1Н-ПИРРОЛ-3-КАРБОКСАМИД МАЛАТА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЕ ОСНОВЕ
CN105712979A (zh) * 2014-12-05 2016-06-29 广州白云山医药集团股份有限公司白云山制药总厂 一种苹果酸舒尼替尼晶型ⅰ的制备方法
EP3539536A1 (en) 2018-03-15 2019-09-18 MH10 Spolka z ograniczona odpowiedzialnoscia A pharmaceutical composition of sunitinib or its salt thereof in its polymorphic form i
WO2020216450A1 (en) 2019-04-25 2020-10-29 Synthon B.V. Pharmaceutical composition comprising amorphous sunitinib
CA3136711A1 (en) * 2019-04-18 2020-10-22 Meter Health, Inc. Methods and compositions for treating respiratory arrhythmias
KR20240025990A (ko) 2022-08-19 2024-02-27 주식회사 스카이테라퓨틱스 무정형 수니티닙, 그 제조방법 및 이를 포함한 의약 조성물

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0592438B1 (en) 1990-10-15 1997-08-27 Pfizer Inc. Indole derivatives
IL100091A (en) 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical preparations containing the physical form of [4] 5) Cyclopentyloxycarbyl (amino 1 methyl indole 3 methyl methyl [3 methoxybenzoyl [2 methylbenzole)
DK0573221T3 (da) 1992-06-05 1998-10-07 Merck Sharp & Dohme Sulfatsaltet af en substitueret triazol, farmaceutiske præparater deraf og deres anvendelse i terapi
AU694419B2 (en) * 1993-03-12 1998-07-23 Zoetis P&U Llc Crystalline ceftiofur free acid
US6288057B1 (en) 1994-08-31 2001-09-11 Eli Lilly And Company Physical form of dihydro-2,3-benzodiazepine derivative
DE19503966C2 (de) 1995-02-07 1998-07-02 Mack Chem Pharm Kristallmodifikation von 2,4-Diamino-6-hydroxymethylpteridin-Hydrobromid, Verfahren zu dessen Herstellung und dessen Verwendung
US5597663A (en) * 1995-05-30 1997-01-28 Motorola, Inc. Low temperature molten lithium salt electrolytes for electrochemical cells
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5673451A (en) * 1995-07-06 1997-10-07 Moore; James R. Instructional toothbrush
US20020045746A1 (en) 1995-12-11 2002-04-18 Barton Kathleen P. Eplerenone crystalline form
US20020038021A1 (en) 1995-12-11 2002-03-28 Barton Kathleen P. Eplerenone crystalline form exhibiting enhanced dissolution rate
US6066647A (en) 1996-07-29 2000-05-23 Pfizer Inc. Zwitterionic forms of trovafloxacin
ATE228117T1 (de) 1996-08-14 2002-12-15 Searle & Co Kristalline form von 4-(5-methyl-3-phenylisoxazol-4-yl)benzolsulfona id
WO1998029344A1 (fr) 1996-12-25 1998-07-09 Nippon Kayaku Kabushiki Kaisha Poudre de cisplatine fine et son procede de production
US5777185A (en) * 1997-09-09 1998-07-07 Laroche Industries Inc. Production of organic fluorine compounds
US6133305A (en) * 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
US6012678A (en) * 1998-01-26 2000-01-11 The Boeing Company Galley vacuum waste disposal system
DE69941672D1 (de) 1998-06-19 2010-01-07 Teijin Ltd Polymorphe modifikationen der 2-(3-cyano-4-isobutylphenyl)-4-methyl-5-thiazol-carbonsäure und verfahren zu ihrer herstellung
ES2192877T3 (es) * 1998-12-17 2003-10-16 Hoffmann La Roche 4-alquenil (y alquinil) oxindoles como inhibidores de kinasas ciclina-dependientes, en particular cdk2.
US6239141B1 (en) * 1999-06-04 2001-05-29 Pfizer Inc. Trovafloxacin oral suspensions
AU1928501A (en) * 1999-11-24 2001-06-04 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
CZ303705B6 (cs) * 2000-02-15 2013-03-27 Sugen, Inc. Pyrrolem substituovaná 2-indolinonová sloucenina pro pouzití jako inhibitor proteinkináz a farmaceutická kompozice s jejím obsahem
US6316672B1 (en) 2001-01-31 2001-11-13 Grayson Walker Stowell Form a of fluoxetine hydrochloride
CN100439360C (zh) 2001-08-15 2008-12-03 法玛西雅厄普约翰美国公司 包括n-[2-(二乙氨基)乙基]-5-[(5-氟-2-氧代-3h-吲哚-3-亚基)甲基]-2,4-二甲基-1h-吡咯-3-甲酰胺的苹果酸盐的晶体、其制备方法和其组合物
WO2009104021A2 (en) 2008-02-21 2009-08-27 Generics [Uk] Limited Novel polymorphs and processes for their preparation
WO2009156837A2 (en) 2008-06-26 2009-12-30 Medichem, S.A. Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt

Also Published As

Publication number Publication date
CU20040029A7 (es) 2008-03-14
DK3168218T3 (en) 2019-01-14
CN1789264A (zh) 2006-06-21
HUP0700036A2 (en) 2008-10-28
US7435832B2 (en) 2008-10-14
EP1419151A1 (en) 2004-05-19
MXPA04001452A (es) 2004-05-20
RS53251B (sr) 2014-08-29
TWI269796B (en) 2007-01-01
PT3168218T (pt) 2019-01-11
SI3168218T1 (sl) 2019-05-31
BR0211612A (pt) 2004-08-24
ES2705063T3 (es) 2019-03-21
ES2623094T3 (es) 2017-07-10
PL216524B1 (pl) 2014-04-30
EP3168218B1 (en) 2018-11-14
UA76483C2 (en) 2006-08-15
US20030069298A1 (en) 2003-04-10
EP2332934B1 (en) 2017-03-01
HRP20040112B1 (en) 2012-03-31
EP2332934A1 (en) 2011-06-15
IS7147A (is) 2004-02-10
KR100639281B1 (ko) 2006-10-31
MA27058A1 (fr) 2004-12-20
PL368317A1 (en) 2005-03-21
NO20041054L (no) 2004-03-12
CN1543462A (zh) 2004-11-03
EA200400183A1 (ru) 2004-08-26
WO2003016305A1 (en) 2003-02-27
AR036261A1 (es) 2004-08-25
CY1121552T1 (el) 2020-05-29
HU229206B1 (en) 2013-09-30
TR201900509T4 (tr) 2019-02-21
DK1419151T3 (da) 2014-03-31
NO326508B1 (no) 2008-12-15
MY139383A (en) 2009-09-30
CN100439360C (zh) 2008-12-03
NZ531232A (en) 2004-11-26
AP1660A (en) 2006-09-09
CN100364991C (zh) 2008-01-30
SI1419151T1 (sl) 2014-04-30
CA2455050A1 (en) 2003-02-27
EA006445B1 (ru) 2005-12-29
EA006445B9 (ru) 2017-02-28
RS10304A (en) 2007-02-05
GEP20063777B (en) 2006-03-27
ECSP044975A (es) 2004-03-23
EP1419151B1 (en) 2014-02-26
KR20040030074A (ko) 2004-04-08
OA12650A (en) 2006-06-19
ME00414B (me) 2011-10-10
JP4159988B2 (ja) 2008-10-01
AU2002324684B2 (en) 2006-10-05
TNSN04028A1 (fr) 2006-06-01
HRP20040112A2 (en) 2004-06-30
ES2453164T3 (es) 2014-04-04
IL160097A0 (en) 2004-06-20
BG108553A (bg) 2005-04-30
CA2455050C (en) 2007-02-20
EP3168218A1 (en) 2017-05-17
CZ2004196A3 (cs) 2005-01-12
US20070191458A1 (en) 2007-08-16
HK1066542A1 (en) 2005-03-24
CU23713B7 (es) 2011-10-05
JP2005503386A (ja) 2005-02-03
AP2004002976A0 (en) 2004-03-31
HK1088008A1 (en) 2006-10-27
SK902004A3 (sk) 2005-03-04
PT1419151E (pt) 2014-03-27
ZA200400706B (en) 2005-05-25

Similar Documents

Publication Publication Date Title
CO5550431A2 (es) Cristales que incluyen una sal de acido malico de n-[2 (dietilamino)etil]-5-[(5-fluoro-2oxo-3h-indol-3-ilideno) metil]-2,4-dimetil-1h-pirrol-3-carboxamida, proceso para su preparacion y composiciones de esta
PE20031012A1 (es) Compuesto inhibidor de la hepatitis c
RU2008139315A (ru) Избирательные андрогенные рецепторные модуляторы
CO4810382A1 (es) Compuestos de indol agentes anti-inflamatorios/analgesicos
PE20040644A1 (es) Nuevos derivados de quinuclidina-amina
BRPI0509795A (pt) composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, uso do composto ou sal farmacologicamente aceitável do mesmo, e, método para promover osteogênese, supressão de ressorção óssea e/ou melhoramento da densidade óssea
MX2008001528A (es) Inhibidores de serina proteasas.
BRPI0417684A (pt) composto, composição farmacêutica, e, uso de um composto
SE0301888D0 (sv) New use VII
PE20070108A1 (es) Control de parasitos en animales con derivados de n-[(feniloxi)fenil]-1,1,1-trifluorometansulfonamida y de n-[(fenilsulfanil)fenil]-1,1,1-trifluorometansulfonamida
CY1105826T1 (el) Μεθοδος συνθεσης του (1s)-4,5-διμεθοξυ-1-(μεθυλαμινομεθυλ)βενζοκυκλοβουτανιου και των αλατων προσθηκης αυτου και εφαρμογη στη συνθεση της ιβαβραδινης και των αλατων προσθηκης αυτης με φαρμακευτικως αποδεκτο οξυ
PE20060693A1 (es) Nuevos derivados de trifluorometansulfonanilida oxamida eter
UY28897A1 (es) Ácido 2-((2-(2-metilaminopirimidin-4-il)-1h-indol-5-carbonil)amino)-3-(fenilpiridin-2-ilamino)propiónico sustancialmente puro como inhibidor de la cinasa ikb
EA200800303A1 (ru) Применение производных и аналогов тиазола при нарушениях, вызванных свободными жирными кислотами
CL2008003324A1 (es) Formulacion farmaceutica liquida de liberacion inmediata que comprende una sal de adicion de acido de un compuesto derivado de azetidina sustituido y un diluyente o portador farmaceuticamente aceptable, util para el tratamiento o prevencion de trombosis.
PE20050012A1 (es) Compuestos de benzopirano como inhibidores de la ciclooxigenasa-2
PE20071034A1 (es) Compuestos heterociclicos como inhibidores de cetp
CL2009001680A1 (es) Composiciones agroquimicas que comprenden a)metconazol o una sal del mismo y b)un acido carboxilico alifatico de cadena lineal o ramificada, saturado o no saturado y donde la relacion molar de (b) respecto de (a) es superior a 1
NO20044041L (no) Okso-azabisykliske forbindelser
CL2007003767A1 (es) Dispersion solida que comprende acido (4r)-4-[n'-metil-n'-(3,5-bistrifluorometil-benzoil)amino]-4-(3,4-diclorobencil)-but-2-enoico n-[(r)-epsilon-caprolactam-3-il]-amida o una sal o solvato de este y un portador; procedimiento de preparacion; composi
AR038332A1 (es) Compuestos que son metabolitos del acido (3-{[(4-terc-butilbencil)-(piridin-3-sulfonil)amino]metil}fenoxi) acetico, composiciones farmaceuticas que los contienen, y procedimiento de determinacion
PE20060001A1 (es) COMPUESTOS DE ß-CETOAMIDA COMO ANTAGONISTAS DE MCH
AR043134A1 (es) Agentes de despigmentacion
BR0314911A (pt) Inibidor de infecção pelo vìrus da dengue e anticorpo monoclonal
UY27960A1 (es) S-(+)-3-(1-(2-(2,3-dihidro -1h-indol-3-il)etil)3,6-dihidro-2h-piridin-4-il)-6-cloro-1h-indol y slaes de adición de ácido del mismo.

Legal Events

Date Code Title Description
FC Application refused